90Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin’s lymphoma: current status and future prospects by Jacobs, Samuel A
© 2007 Dove Medical Press Limited.   All rights reserved
Biologics: Targets & Therapy 2007:1(3) 215–227 215
REVIEW
90Yttrium ibritumomab tiuxetan in the treatment 
of non-Hodgkin’s lymphoma: current status
and future prospects
Samuel A Jacobs
University of Pittsburgh School 
of Medicine, 5150 Centre Avenue, 
Pittsburgh, PA, USA
Correspondence: Samuel A Jacobs
University of Pittsburgh School of 
Medicine, 5150 Centre Avenue, Pittsburgh, 
PA 15232, USA
Tel +1 412 235 1278
Fax +1 412 623 4655
Email jacobssa@upmc.edu
Abstract: After nearly three decades with little change in the treatment for B-cell non-Hodgkin’s 
lymphoma, the addition of immunotherapy has had a profound effect on the treatment of 
this group of diseases. A more subtle addition to the armentarium has been the radiolabeled 
monoclonal antibodies, 90yttrium ibritumomab tiuxetan and 131iodine tositumomab. Unfortu-
nately these drugs have been underutilized. This is, in part, because of the need for coordination 
between specialties, concern about long-term effects, possible limitations on the tolerance of 
subsequent therapies and, in part, because of reimbursement factors. In this review, the studies 
in relapsed and refractory disease are discussed and the very promising results reported from 
phase II studies using radioimmunotherapy as ﬁ  rst-line. Potential mechanisms of resistance to 
monoclonal antibodies are postulated based on alterations in cell signaling pathways that have 
been observed in lymphoma cell lines resistant to rituximab. It is anticipated that as mechanisms 
of resistance are better understood for both unlabeled and labeled monoclonal antibodies, 
biomarkers will not only predict their efﬁ  cacy but also lead to the development of therapies to 
overcome resistance.
Keywords: immunotherapy, radioimmunotherapy, ibritumomab, zevalin, non-Hodgkin 
lymphoma
Introduction
The non-Hodgkin’s lymphomas (NHL) are a diverse group of lymphoid neoplasms 
that collectively rank ﬁ  fth in cancer incidence and mortality in the US (Parker et al 
1996; Müller et al 2005). The incidence and prevalence of NHL has risen 150% over 
the past few decades (Aisenberg 1995; Edwards et al 2005) The incidence increases 
with age, as most patients are older than age 60 at diagnosis, and males overall are 
affected about 1.5 times more often than females. In 2007, it is estimated that there 
will be 63,000 new cases and over 18,000 deaths in the US from NHL (National 
Cancer Institute 2007).
NHL are categorized according to the World Health Organization (WHO) clas-
siﬁ  cation. The WHO system was developed to help standardize the diagnosis of 
lymphomas based on histologic, molecular, genetic, and immunologic criteria. The 
majority of adult lymphomas are B cell in origin; the most common subtypes are 
follicular lymphoma and diffuse large B-cell lymphoma which account for 25% and 
35% of cases, respectively. Other less common subtypes of B-cell lymphoma include 
mantle cell lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma 
(Harris et al 2000; World Health Organization 2001).
Approximately, 95% of B-cell lymphomas have a CD20 surface antigen. CD20 
(membrane-spanning 4-domain, group A, member 1) is a nonglycosylated protein 
of 33 to 35 kDa expressed on the cell surface of human B lymphoctyes. The gene Biologics: Targets & Therapy 2007:1(3) 216
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for CD20 (MS4A1) is switched on at the pre-B-cell stage 
of B-cell development, expressed throughout B-cell 
maturation, and lost during ﬁ  nal maturation to plasma cells 
(Cartron et al 2004). The conﬁ  guration of CD20, which 
is anchored in the cell membrane, protects antigen shed-
ding. CD20 is expressed on the B-cell at a high density in 
excess of 100,000 copies per cell but does appear to vary 
by histologic subtype. The exact function of CD20 has not 
been fully elucidated. There is no ligand to CD20 that has 
been identiﬁ  ed; and mice that are CD20-deﬁ  cient do not 
demonstrate abnormal B-cell function. However, studies 
suggest that CD20 serves as a kinase in Ca2+ inﬂ  ux across 
plasma membranes and in doing so may have a role in 
regulating cell cycle progression (Golay et al 1985). Anti-
CD20 monoclonal antibodies have an effect on regulation of 
the cell cycle and induce a wide variety of signaling events 
which lead to the induction of apoptosis, as well as through 
a number of other potential mechanisms.
Rituximab is a chimeric murine/human monoclonal 
antibody produced by recombinant technology from the 
parent murine monoclonal antibody, ibritumomab. It binds 
speciﬁ  cally to the CD20 antigen with an apparent avidity 
5–11 nM in vitro which is about one log greater than its 
parent murine antibody (IDEC Pharmaceuticals 2001). It 
was engineered by fusing the light- and heavy-chain variable 
domains of 2B8 murine monoclonal anti-CD20 antibody and 
human kappa light-chain and gamma 1 heavy-chain constant 
regions (Reff et al 1994). In 1997 it became the ﬁ  rst mono-
clonal antibody for hematologic malignancies approved by 
the US Food and Drug Administration (FDA).
The anti-CD20 monoclonal antibody, rituximab, appears 
to have several mechanisms of action and their relative 
inﬂ  uence on these mechanisms may account for differ-
ences in sensitivity across hisotologic subtypes of B-cell 
lymphomas. In vitro studies indicate that rituximab induces 
complement-dependent cytotoxicity (CDC) in B-cell lym-
phoma lines. This CDC lysis correlates in part with the 
level of CD20 expression but may also be dependent on the 
interaction with complement regulatory proteins (Golay et al 
2000, 2001; Treon et al 2001). The increase in complement 
activation products which often occurs with the ﬁ  rst infu-
sion of rituximab has been described as “cytokine-release 
syndrome” (Winkler et al 1999) with associated fever, rigors, 
headache, and rarely cardiovascular collapse.
Antibody-dependent cytotoxicity (ADCC) is another 
mechanism that results in tumor cell lysis. Binding of the 
antibody to the target antigen allows for the recruitment 
of effector cells such as NK cells and macrophages, which 
express Fc receptors. These cells are then directed toward 
the target cells inducing either phagocytosis or release 
of their cytotoxic granules to promote cell killing. There 
are several classes of Fc receptors. The presence of the 
FcγRIIIa genotype correlates with clinical and molecular 
responses in untreated follicular lymphoma conﬁ  rming that 
ADCC is an important mechanism of action of rituximab 
(Cartron et al 2002; Weng and Levy 2002, 2003). One 
of the effects of the immunomodulatory derivatives is to 
enhance N-K cell activity. It is of interest that prelimi-
nary data suggests potent synergy of the combination of 
thalidomide, a potential stimulator of N-K cell activity, 
and rituximab in relapsed mantle cell lymphoma. This 
possible synergy merits further investigation particularly as 
more potent immunomodulatory analogs become available 
(Kaufmann et al 2004).
Several studies have indicated that the maximal clinical 
response to rituximab may take several months suggesting 
additional mechanisms of action. One such hypothesis is that 
peptides from lysed lymphoma cells are presented to dendritic 
cells with the generation of speciﬁ  c cytolytic T lymphocytes 
(Kalergis and Ravetch 2002; Raﬁ  q et al 2002; Selenko et al 
2002). While there are experimental data in murine models 
supporting this passive immunotherapy model, human data 
are lacking.
Mechanism of resistance to monoclonal antibody therapy 
are under investigation. The clinical observations are that 
previously untreated patients with low-grade and follicular 
lymphoma have a much higher overall response rate and 
complete response rate than patients with prior treatment, and 
that, patients will eventually become resistant or refractory 
to rituximab therapy. There are many possible explanations 
for this resistance. In vitro manipulation of the extracellular 
epitope of the CD20 loop alters the binding to anti-CD20 
monoclonal antibodies, and thus, suggests that critical muta-
tions in CD20 may be one mechanism of resistance (Binder 
et al 2006). In another model using rituxiamb sensitive and 
resistant cell clones, surface CD20 expression has been dem-
onstrated to be diminished in resistant line (Czuczman et al 
2004). Studies of the phenotypic cell signaling proﬁ  les of 
rituximab sensitive and resistant cell clones demonstrate that 
rituximab failed to chemosensitize rituximab-resistant clones 
which exhibited constitutively hyperactivation of NF-kB and 
ERK1/2 pathways, which leads to overexpression of resis-
tance factors such as Bcl-2, Bcl-xL, and Mcl-1 (Jazirehi et al 
2004, 2005, 2007). An understanding of altered cell signaling 
and resistance may have implications for combining agents 
which will reverse resistance.Biologics: Targets & Therapy 2007:1(3) 217
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At the same time that preclinical and clinical evaluation 
was taking place with unlabeled anti-CD20 monoclonal 
antibody, radiolabeling technologies made it possible to 
chelate radioactive isotopes to monoclonal antibodies, which 
retain their speciﬁ  city and could provide targeted delivery 
of localized radiation (Chinn et al 1999). Anti-CD20 radio-
immunoconjugates, which link the isotopes 90yttrium (90Y) 
and 131iodine (131I) to murine monoclonal antibodies, were 
subsequently approved by the US FDA for the treatment of 
relapsed, and refractory low-grade lymphoma in 2002 and 
2003, respectively. Radioimmunoconjugates are an attractive 
therapeutic option for lymphomas presumably because of the 
inherent sensitivity of malignant lymphoma cells to ionizing 
radiation coupled with the mechanism of action associated 
with anti-CD20 binding. The popular thinking is that high 
energy isotopes will delivery targeted radiation. In the case 
of 90Y-ibritumomab tiuxetan, the radiolabel is a pure beta 
emitter with a short path length. This means that 90% of 
the dose is delivered within a range of 5 mm in tissue. This 
equates to a few hundred cell diameters and provides the 
thesis for a radiation crossﬁ  re effect in which cell kill can 
occur not only to cells with bound antibody but also cells 
at some distance which may not bind antibody and, hence, 
may be particularly beneﬁ  cial in bulky or poorly vascularized 
tumors (Jacobs et al 2005; Skvortsova et al 2005). In a small 
pilot clinical study, intratumoral distribution of monoclonal 
antibody and quantitative assessment of radioactivity was 
examined in patients’ nodal tissues sampled after therapy 
with  90Y-ibritumomab tiuxetan by autoradiography and 
measuring decay events. There was a general correlation 
between radioactivity in the tissue, isotopic localization to 
the cell surface membrane and response to therapy. A failure 
to bind to malignant lymphocytes would appear to be one 
explanation for lack to response to radioimmunotherapy 
(RIT) (Jacobs et al 2005) (Figure 1).
Several in vitro studies suggest that there are more com-
plex mechanisms accounting for the additive or synergistic 
effects of radiation and monoclonal antibody therapy. When 
combining rituximab and external beam radiation there was 
a synergistic increase in expression of proteins involved in 
apoptosis and cell-cycle regulation (Skvortsova et al 2005). 
In these in vitro studies, enhanced antiproliferative and apop-
totic effects of rituximab and radiation were achieved through 
inhibition of c-myc and Bcl-xL expression. In another model 
evaluating the interaction between radiation and a monoclo-
nal antibody, ionizing radiation was observed to trigger epi-
dermal growth factor (EGF) import into the nucleus and as a 
consequence increase in DNA-repair kinase activity. By pre-
treatment with anti-EGFR antibody DNA repair was inhibited 
and resulted in increased radiosensitivity of the treated cells 
(Milas et al 2000; Dittman et al 2005). In another murine 
lymphoma model, I-131 labeled anti-MHC class II monoclonal 
antibody, while an excellent vector to deliver radiotherapy 
to a target, did not result in long-term clearance of tumor. 
However, by combining the radiation delivery antibody with 
an unlabeled anti-idiotype (Du et al 2007) long-term tumor 
eradication was observed. Clinical data supporting an addi-
tive effect of radiation and monoclonal antibody come from 
a study in patients with relapsed/refractory B-cell lymphoma 
patients in which unlabeled tositumomab was compared with 
131I-tositumomab. The overall response favored the radiola-
beled monoclonal antibody 55% versus 19%. In addition 13 
of 19 patients crossed over from the unlabeled antibody to 
the labeled antibody responded (Davis et al 2004). Additional 
study is needed to elucidate more fully the effects of ionizing 
irradiation and monoclonal antibody to realize the potential 
of this therapy.
90Y-ibritumomab tiuxetan (Zevalin®) and 131I-tositumomab 
(Bexxar®) are FDA-approved for therapy for relapsed or 
refractory low-grade lymphoma with or without transfor-
mation. Ibritumomab, the murine IgG1 anti-CD20 antibody 
that is the parent of the chimeric antibody rituximab, is 
covalently linked to the MX-DTPA linker-chelator tiuxetan, 
which provides a high-afﬁ  nity chelation site for 90Y or for 
scanning purposes to 111indium (111In). As mentioned above, 
90Y is a pure beta emitter with a half-life of 64 hours and a 
maximum energy of 2.3 MeV and a mean path length in 
soft tissue of 5.3 mm. With 90Y-ibritumomab tiuxetan, the 
radiation absorbed dose is primarily delivered to the region 
of binding with minimal free yttrium in the serum or cleared 
in the urine, thus allowing the prescribed dose to be based on 
a ﬁ  xed amount of radioactivity per body weight. The dose 
of 90Y-ibritumomab tiuxetan is calculated by body weight 
in kilograms and is 0.4 mCi/kg for patients with a platelet 
count 150,000 × 109/mL or 0.3 mCi/kg for a platelet count 
Figure 1 Autoradiographic localization of 90Y-ibritumomab tiuxetan from lymph 
node on a patient sampled 4 days after treatment.Biologics: Targets & Therapy 2007:1(3) 218
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between 100,000 and 149,000 × 109/mL. The maximum dose 
administered is 32 mCi. The 90Y-ibritumomab regimen can 
be conveniently administered over one week as an outpatient. 
On day 1, rituximab at 250 mg/m2 is infused and within 
4 hours of completion, a tracer dose of 111In ibritumomab, 
5 mCi, is administered over 10 minutes. Gamma scanning 
is performed once at 24–72 hours to conﬁ  rm the expected 
biodistribution. On day 8, rituximab is repeated at 250 mg/m2 
and the therapeutic dose of 90Y-ibritumomab tiuxetan is 
administered (Dillman 2002). Following treatment with 
90Y-ibritumomab tiuxetan, patients do not require isolation 
and only minimal radiation precautions are required such as 
avoiding contact with bodily ﬂ  uids for the ﬁ  rst week after 
treatment (Witzig et al 1999, 2003a; Dillman 2002; Wiseman 
et al 2002; White 2004; Johnston et al 2006).
Tositumomab, a murine IgG2a monoclonal antibody spe-
ciﬁ  c for CD20, is labeled with 131I. 131I is a beta and gamma 
emitter with a half-life of 8 days, maximum particle energy 
of 0.5 MeV and a path length of 0.8 mm. Because of indi-
vidual patient variability in clearance of 131I-tositumomab, a 
dosimetric dose consisting of 10 mg of antibody labeled with 
approximately 5 mCi 131I is administered over 30 minutes. 
Using a NaI scintillation probe and gamma camera, serial 
total body radioactivity counts are obtained and total-body 
clearance kinetics are measured over three time points in order 
to calculate the millicuries to produce a total body therapeutic 
dose of 75 cGy for patients with a platelet count  150,000 × 
109/mL and 65 cGy for patients with a platelet count of 
100,000 to 149,000 × 109/mL. As the 131I-conjugated anti-
body is metabolized, free 131I metabolites are released into 
the bloodstream and rapidly excreted in the urine. Patients 
receive potassium iodide 120 mg daily, as thyroid blockage, 
administered from 24 hours prior to the dosimetric dose and 
continued for 14 days after the therapeutic administration. 
Institutional policies vary with regard to in-patient or 
out-patient administration of 131I-tositumomab (Vose et al 
2000; Kaminski et al 2000, 2001).
The major toxicity with both radiolabeled antibodies 
is reversible myelosuppression. The hematologic toxicity 
tends to occur at 5–7 weeks after treatment and may take 
2–4 weeks for recovery. With 90Y-ibritumomab tiuxetan, 
Grade 4 neutropenia, thrombocytopenia, and anemia occurred 
in 30%, 10% and 4% of patients, respectively (Witzig et al 
2003a). Growth factors, blood and platelet transfusion sup-
port are required in about 20% of patients (Dillman 2002). 
Hematologic toxicity increased with the degree of bone 
marrow involvement, number of prior regimens, and prior 
therapy with ﬂ  udarabine. Two studies report treatment of
patients with 90Y-ibritumomab tiuxetan and one report of 
131I-tositumoab with prior high-dose therapy with manageable 
hematologic toxicity (Kaminski et al 2000; Vose et al 2003; 
Jacobs et al 2005). In a review of 349 patients treated with 
90Y-ibritumomab tiuxetan for safety, the grade 3 or 4 non-
hematologic toxicities occurred in 11% of patients; asthenia 
was most common and occurred in only 6 patients. Hospital-
izations with infection during the treatment period occurred 
in 23 patients (7%) with 6 patient having neutropenic fever 
(Witzig et al 2003a). Hematologic toxicities are similar with 
131I- tositumomab. Human anti-mouse antibodies (HAMA) 
may be detected in the serum in approximately 2% of heavily 
pretreated patients with the 90Y-ibritumomab tiuxetan and 
10% of heavily pretreated patients with the 131I-tositumomab 
(Kaminski et al 2001). However, HAMA were detected in 48 
of 76 (63%) previously untreated patients with follicular lym-
phoma following infusion with 131I-tositumomab (Kaminski 
et al 2005). The potential advantages of a HAMA or human 
anti-globulin antibody (HAGA) have not been generally 
appreciated and are not well studied after ibritumomab or 
tositumomab. However, following administration of RIT, the 
development of polyclonal HAGA directed against epitopes 
on the administered antibody may generate anti-idiotypic 
antibody that can mimic the tumor antigen and facilitate host 
recognition of the tumor. This may have a clinical beneﬁ  t 
(DeNardo et al 2003; Azinovic et al 2006). Certain murine 
antibody-based assays such as prostate-speciﬁ  c antigen may 
be unreliable in HAMA positive patients. A major long-term 
concern with both radiolabeled antibodies has been the 
potential for myelodysplasia and acute leukemia. Thus far, 
it appears to be about 3%, which is the frequency of these 
toxicities in lymphoma patients receiving extensive chemo-
therapy (Czuczman et al 2004; Bennett et al 2005). In the 
study of 76 previously untreated patients who received 131I-
tositumomab, there have been no cases of MDS (Kaminski 
et al 2005). Another delayed toxicity of 131I-tositumomab 
is hypothyroidism, which may occur in a small number 
of patients despite pretreatment with potassium iodide 
(Kaminski et al 2000).
Patients relapsing after radioimmunotherapy can be treated 
feasibly with subsequent therapy. In 58 patient treated after 
90Y-ibritumomab failure at a single institution, the median 
number of additional regimens was two (range one to seven). 
The therapies ranged from single agent chemotherapy to com-
bination regimens to bone marrow transplant. The tolerability 
of salvage treatment seemed to be similar to the same salvage 
therapy in patients who did not receive ibritumomab (Ansell 
et al 2002). Relapsed patients can safely receive radiation. In Biologics: Targets & Therapy 2007:1(3) 219
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a recent report 20 of 26 sites in 19 patients responded to radia-
tion after 90Y-ibritumomab tiuxetan. There were no unexpected 
toxicities (Justice et al 2006).
Treatment of relapsed or refractory 
patients with follicular lymphoma 
with 90Y-ibritumomab tiuextan
There are multiple studies which demonstrate the efﬁ  cacy of 
both ibritumomab tiuxetan and tositumomab in relapsed and 
rituximab-refractory follicular lymphoma (Kaminski et al 
2001; Witzig et al 2002a, b). This review will focus mainly on 
the studies with 90Y-ibritumomab tiuxetan. The entry criteria 
in the pivotal studies with 90Y-ibritumomab tiuxetan required 
adequate bone marrow reserve as determined by peripheral 
counts showing absolute neutrophils of at least 1500 × 109/mL 
and a platelet count of 100,000 × 109/mL. Bone marrow 
criteria included a cellularity of at least 15% of the marrow 
space and less than 25% of the marrow space occupied 
by lymphoma. Patients with prior high-dose therapy with 
bone marrow rescue were excluded. Under these circum-
stances, it was established that for patients with a platelet 
count of 100,000 × 109/mL to 149,000 × 109/mL, a dose of
0.3 mCi/kg was well tolerated and that for patients with 
a platelet count >150,000 × 109/ml, a dose of 0.4 mCi/kg 
was well tolerated. The maximum dose for either group was 
32 mCi/kg. The randomized, multicenter phase III study that 
compared 90Y-ibritumomab tiuxetan to rituximab included 
143 patients. Eligible patients had prior chemotherapy but 
were rituximab naïve. There were 113 patients with follicular 
lymphoma, 17 patients with non-follicular low-grade 
lymphoma and 13 patients with transformed lymphoma. 
Patient characteristics were well balanced with Stage III/IV 
disease in 90% and mean and median prior treatments of 
2 in each arm. The overall response rate (ORR), complete 
response rate and complete response rate unconﬁ  rmed (CR 
and CRu) were 80% and 34% for 90Y-ibritumomab tiuxetan 
and 56% and 20% for rituximab. Age did not predict response
rate nor toxicity but patients with bulky disease faired 
less well. The estimated median duration of response for 
the follicular lymphoma patients was 18.5 months versus 
12.1 months favoring the 90Y-ibritumomab arm (Witzig et al 
2002b). In a single arm study patients with rituximab refrac-
tory follicular lymphoma were treated with 90Y-ibritumomab 
tiuxetan. Rituximab refractory is deﬁ  ned as failure to respond 
to rituximab or relapse within 6 months of the last course 
of therapy. Fifty-four patients with a median number of 4 
prior regimens had an overall and complete response rate of
74% and 15% respectively. The median duration of response 
was estimated to be 6.4 months (Witzig et al 2002a) In an 
analysis of 1177 patients treated with 131I-tositumomab, 
overall response, complete response and duration of response 
decreased as the number of prior therapies increased (Gregory 
et al 2005). In Table 1, the response rate and duration of 
response in patients with follicular lymphoma are compared 
based on the prior therapy. The decrease in complete response 
and duration of response is striking most likely reﬂ  ecting 
effect of prior therapy and not inherent differences in the 
efﬁ  cacy of the radioimmunotherapies.
First-line treatment of follicular 
lymphoma with RIT alone or in 
sequence
There is one study which has used radioimmunotherapy 
as ﬁ  rst-line single agent therapy in follicular lymphoma. 
Seventy-six patients with follicular lymphoma, stage III 
and IV, and grade 1 or 2 histology received tositumomab. 
The overall response and complete response rates were 95% 
and 75% respectively. The ability to achieve a complete 
response was decreased in patients with a bulky mass of at 
least 5 cm and if bone marrow involvement was present. At 
the time of publication, the median follow-up was 5.1 years, 
the actuarial 5-year progression-free survival was 59% and 
the median progression-free survival was 6.1 years. The 
annualized rate of relapse was 25% during the ﬁ  rst year and 
decreased to 13% in the second year, 12% in the third year, 
and 4.4% per year after 3 years (Kaminski et al 2003a). Non-
hematologic toxicities were mild, mostly infusion-related and 
with low incidence of headache, arthralgias, and myalgias. 
Table 1 Effect of prior treatment on response to radioimmunotherapy (RIT) in follicular lymphoma (FL)
No. of   RIT   Prior   Prior   Complete   Any   Duration 
patients     chemotherapy  rituximab   response %   response %   in months 
76 (Kaminski et al 2005)  131I   No   No   75   95   73 
73 (Witzig et al 2002b)  90Y   Yes   No   30   86   14.2 
57(Witzig et al 2002a)  90Y   Yes   Yes   14   70   6.4 Biologics: Targets & Therapy 2007:1(3) 220
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In long-term follow-up 13% of patients required thyroid 
replacement. There were no cases of myelodysplastic syn-
drome or acute leukemia observed after a median follow-up 
of 5.1 years. Antimouse antibodies (HAMA) were detected 
in 63% of patients. The antibodies were detected a median of 
3.3 weeks after the dosimetric dose of 131I-tositumomab and 
remained detectable for a median of 5.5 months. The devel-
opment of high levels of HAMA within the ﬁ  rst two weeks 
of the therapeutic dose was associated with fever, myalgias, 
arthralgia, or rash lasting 3–4 days without apparent sequelae. 
Thus, in selected patients, a single dose of 131I-tositumomab 
appears both safe and effective.
There are 6 studies that have employed chemotherapy 
followed by RIT as part of ﬁ  rst-line therapy (Link et al 
2004; Shipley et al 2004; Leonard et al 2005; Press et al 
2006; Zinzani et al 2006; Jankowitz et al 2007). As shown 
in Table 2, each of these studies reports a high complete 
response rate ranging from 67% to 90%. But, in addition, 
each of these studies suggests that the complete response 
rate nearly doubled after RIT. In evaluating these and future 
studies, it is essential to compare characteristics such as 
Follicular Lymphoma International Prognostic Index (FLIPI) 
score (Solal-Céligny et al 2004), bulk of disease, histologic 
grade, and criteria for determination of complete response. 
In one study, 59 of 60 patients had a baseline positive PET 
scan. Restaging imaging included either a fused PET-CT or a 
PET and CT and followed the recently revised guidelines for 
staging NHL (Cheson et al 2007; Juweid et al 2007). There 
is 10% discordance between using CT criteria for complete 
response or CRu and a negative PET scan. Also in this study, 
the majority of patients had marrow involvement, two-thirds 
had intermediate or high FLIPI score, and half the patients 
had masses greater than 5 cm and histologic grade 2 or 3. 
Combining PET and CT scans for evaluation of response, the 
complete response rate doubled following RIT (Jankowitz 
et al 2007). Some of these studies included measurement 
of BCL-2 rearrangement in blood or bone marrow. In these 
subset analyses, conversion of BCL-2 from positive to 
negative in blood and/or bone marrow correlated with pro-
longed remission. Several clinical trials suggest that patients 
achieving a molecular response have a signiﬁ  cantly longer 
failure-free survival than those who did not (Czuczman et al 
2001; Lehy et al 2006). The implication is that the depth 
of complete response is greater in patients with a complete 
response who have converted from PRC positive BCL-2 in 
blood or bone marrow to PRC negative. While it is often cited 
that the t(14; 18) translocation of the BCL-2 proto-oncogene 
is expressed in blood or bone marrow in 80% of patients with 
follicular lymphoma, the detection rate in recent phase II 
studies has been substantially lower, 40%–70% (Kaminski 
et al 2005; Press et al 2006; Jankowitz et al 2007). In future 
studies, it may be informative to correlate PET scan negativ-
ity with minimal residual disease as determined by BCL-2 
assay. However, as yet there is not a standardized, uniformly 
accepted polymerase chain reaction (PCR) assay to measure 
BCL-2 rearrangement. As a look into the future, it seems 
likely to us that determination of cell signaling pathways will 
be predictive of response to monoclonal antibody therapy and 
be useful in delineating the mechanisms of synergy between 
targeted radiation and the effects of anti-CD20 therapy. For 
now, we await the results of the Intergroup S0016 which 
is a phase III randomized study comparing CHOP-R with 
CHOP followed by 131I-tositumomab in previously untreated 
patients with follicular lymphoma. The primary endpoint is 
progression-free survival and secondary outcomes are overall 
response rates and toxcities.
Marginal zone B cell lymphoma
This subtype of NHL accounts for about 8% of lymphomas 
and include nodal and extranodal marginal zone lymphoma, 
gastric mucosa-associated lymphoid tissue and splenic zone 
lymphoma. The immunophenotype of marginal lymphomas 
is distinct from other small lymphocytic lymphomas: the 
antigen proﬁ  le for the marginal zone lymphomas include 
CD19, CD20, CD22 positive and CD5, CD10, CD23, and 
CD11C negative. In a phase II study including 34 patients 
with gastric and non-gastric marginal zone lymphoma of 
which 23 had no prior therapy, rituximab produced an 
overall and complete response rate of 73% and 44%, respec-
tively. The median duration of response was 10.5 months. 
Studies with radioimmunotherapy are limited with these 
patients included in phase II studies of low-grade NHL. 
The randomized study of 90Y-ibritumomab versus rituximab 
included 9 patients on the ibritumomab arm with nonfol-
licular low grade lymphoma. Two of these patients had 
Table 2 First-line therapy in follicular lymphoma (FL) with 
sequential chemotherapy followed by radioimmunotherapy (RIT)
Author Chemotherapy  RIT  No.  of  CR
     patients
Leonard et al 2005  F × 3   I-131  35  86% 
Zinzani et al 2006  FM × 6   Y-90  19  73% 
Press et al 2006  CHOP × 6  I-131  90  69% 
Shipley et al 2004  CHOP-R × 3  Y-90  22  86% 
Link et al 2004  CVP × 6   I-131  30  80% 
Jankowitz et al 2007  CHOP-R × 3  Y-90  60  90%
 R  × 4Biologics: Targets & Therapy 2007:1(3) 221
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marginal zone lymphomas and both achieved a complete 
response (Witzig et al 2002b). A study using 131I-rituximab 
included 6 patients with marginal lymphoma who relapsed 
after prior therapy, all responded and 5 achieved a complete 
response (Lehy et al 2006).
Mantle cell lymphoma
Mantle cell lymphoma (MCL) is a distinct entity with char-
acteristic histological appearance, phenotypic proﬁ  le and 
chromosomal translocation, t(11; 14). The antigen proﬁ  le 
includes CD20, CD19 and CD5 positive, and is BCL-2 and 
cyclin D1 positive but usually CD10 and BCL-6 negative. 
Like follicular lymphoma, mantle cell lymphoma is sensi-
tive to radiation with local tumor being very responsive. 
About a third of patient with relapsed mantle cell lym-
phoma will respond to radioimmunotherapy. In a study of 
15 patients with heavily pretreated MCL (median number 
of 3 prior regimens and a range of 1 to 6), who were treated 
with  90Y-ibritumomab tiuxetan, there were 5 objective
responses and a median response duration of 5.7 months 
(Oki et al 2004). A phase II trial from the European MCL 
Network treated relapsed mantle cell lymphoma patients 
with cytoreductive therapy followed by ibritumomab. 
A complete response occurred in 2 of 16 patients after che-
motherapy with 7 of 14 partial responders achieving a com-
plete response after RIT (Oki et al 2004). An ECOG phase II 
trial that recently completed accrual in previously untreated
MCL patients treated with CHOP-R × 4 cycles followed 
by 90 Y-ibritumomab tiuxetan reported a complete response 
rate after CHOP-R of 14% with an increase to 45% after 
90Y-ibritumomab tiuxetan (Smith et al 2006). High-dose 
myeloablative radioimmunotherapy has been used alone and 
in combination with high-dose chemotherapy in relapsed 
mantle cell lymphoma. Seven patients with relapsed mantle 
cell lymphoma, all of who had received CHOP or CHOP-
like regimens as ﬁ  rst-line therapy, and also relapsed after 
high-dose chemotherapy with autologous stem cell trans-
plantation were treated with a myeloablative dose of 131I 
C2B8 (rituximab) (Behr et al 2002). Six patients achieved 
a complete response and with a median follow-up of 
25 months, 5 patients are still in complete response at time 
of publication. Sixteen patients with relapsed mantle cell 
lymphoma with a median of three prior regimens received. 
131I-tositumomab at a median dose of 510 mCi and 8–13 
days later received high-dose etoposide/cyclophosphamide 
with autologous stem cells. Twelve patients had no progres-
sion of lymphoma 6–57 months after treatment with overall 
survival and progression-free survival at 3 years estimated 
to be 93% and 61%, respectively (Press et al 2000). Another 
approach in relapsed mantle cell lymphoma is to sequence 
bortezomib with RIT to determine if drug resistance can 
be overcome. Additional clinical trials employing RIT will 
be necessary to determine the role of RIT in mantle cell 
lymphoma and to deﬁ  ne optimal treatment strategies.
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous 
group of aggressive lymphomas which accounts for about 
30% of all NHL (Armitage and Weisenburger 1998). Gene 
expression array data have demonstrated that DLBCL is a 
heterogeneous group of diseases based on the tumor genotype 
(Alizadeh et al 2000). At least 3 distinct genetic types were 
identiﬁ  ed. The most common type, occurring in 40% of 
the cases, was associated with rearrangements of BCL-6 
in the absence of other known genetic lesions. The second 
type involved the activation of BCL-2 (Gascoyne et al 1997). 
Cases with neither BCL-2 or BCL-6 rearrangements com-
promise the third genetic group of DLBCL. These genetic 
subgroups have prognostic relevance since the presence of 
BCL-2 confers a poor prognosis, while the presence of BCL-6 
denotes a favorable prognosis (Ye et al 1993). DLBCL can 
arise de novo, or may transform from a low-grade lymphoma 
such as small B cell lymphoma or follicular lymphoma.
In the initial studies with 90Y-ibritumomab tiuxetan, eli-
gible patients included transformed and intermediate grade 
diffuse large B-cell lymphoma. At least a partial response was 
observed in 11 of 23 patients (Witzig et al 2002a). A series 
of patients at least 60 years old with relapsed or refractory 
DLBCL where treated with 90Y-ibritumomab tiuxetan and 
analyzed according to prior therapy. The overall response rate 
and median survival of approximately 50% and 22 months, 
respectively, and were similar in induction failures and relapse 
from complete remission if they did not have prior rituximab; 
however, the group of patients relapsing after chemotherapy 
and rituximab had a overall response rate and median sur-
vival of approximately 20% and 4.6 months (Morschhauser 
et al 2007). This is of interest because it indicates that resis-
tance to antibody is itself sufﬁ  cient to largely abrogate the 
effects of radiation. Several studies with slightly different 
designs are evaluating chemotherapy-rituximab followed by 
90Y-ibritumomab compared with chemotherapy-rituximab 
alone as ﬁ  rst-line therapy.
Small lymphocytic lymphoma
Small lymphocytic lymphoma (SLL) is the nodal counterpart 
of chronic lymphocytic lymphoma. SLL cells have a lower Biologics: Targets & Therapy 2007:1(3) 222
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density of CD20 than other B cell malignancies. In clini-
cal trials, SLL has a lower response rate to rituximab than 
follicular lymphoma. The poor response rate to rituximab 
is particularly striking in patients who have failed prior 
therapy. Combining three series, 6 of 49 patients with prior 
therapy responded to single agent rituximab (McLaughlin
et al 1998; Davis et al 1999; Piro et al 1999). This is 
contrasted to responses with single-agent therapy in 15 of 
22 patients with no prior therapy (Hainsworth et al 2003). 
A small number of patients with SLL were included in 
the early trials with 90Y-ibritumomab. In one study 3 of 
6 patients achieved a partial response (Witzig et al 2002b), 
and in the study of patients with mild thrombocytopenia, 
SLL patients treated with 90Y-ibritumomab, the response 
rate in small lymphocytic lymphoma and transformed B-cell 
lymphoma was noted to be signiﬁ  cantly lower than in fol-
licular lymphoma (Wiseman et al 2002). In our personal 
experience, the response rate in SLL is poor and all the 
responses have been partial.
Radioimmunotherapy and high-dose 
chemotherapy with stem cells
There are several phase I/II and phase II studies combin-
ing either 90Y-ibritumomab tiuxetan or 131I-tositumomab 
either alone or with high-dose chemotherapy and stem 
cell rescue (Press et al 2000; Gopal et al 2003; Winter 
et al 2004; Nademanee et al 2005; Vose et al 2005). 
With 131I-tositumomab, the target dose of radiation to the 
critical normal organs such as lung, liver and kidneys was 
2000–2700 cGy. Using the standard dose of 131I to achieve 
a total body dose of 75 cGy, depending upon dosimetry, 
the actual 131I dose varies from 1184 to 8510 MBq. By 
comparison, with the high dose regimen the actual 131I dose 
varies from 10064 to 31080 MBq. The regimens employing 
90Y-ibritumomab tiuxetan deliver a target dose of 1000 cGy 
to highest normal organ with a median administered dose 
of 71.6 mCi (range 36.6–105 mCi). The maximum con-
ventional dose of 90Y-ibritumomab tiuxetan is 32 mCi. 
These studies have shown that it is feasible to give high 
dose of RIT and further that there is no additional toxicity 
of combining high-dose RIT with high-dose chemotherapy 
with stem cell rescue. To date in phase I/II and phase II 
studies, overall response rates have been substantial in 
diffuse large B-cell, follicular lymphoma and mantle cell 
lymphoma. However, in the absence of larger, compara-
tive studies it remains difﬁ  cult to sort out the role of each 
component such as high-dose chemotherapy alone or with 
high- vs low-dose radioimmunotherapy.
Unusual adverse events
Anaphylactic reaction
The package inserts for RIT warn of allergic reactions 
such as angioedema, acute respiratory distress, hypoxia, 
bronchospasm, and even anaphylactic shock with first 
exposure to the monoclonal antibody component of the 
drug. There are a few series of cases in which responders to 
RIT have been re-treated. One report describes 32 patients 
who because of initial response to 131I-tositumomab, were 
re-treated with 131I-tositumomab tiuxetan. The overall and 
complete response rates to re-treatment were 52% and 25%, 
respectively. The median duration of compete response was 
35 months. One patient experienced an anaphylactoid-type 
reaction associated with unlabeled tositumomab infusion 
during the therapeutic dose. In another phase I study in 
which 15 patients received a sequential second dose of 
90Y-ibritumomab tiuxetan, there were no unexpected side 
effects reported (Witzig et al 2003b). The overall response 
rate was 83%. We reported a case of an anaphylactic reaction 
in a 45-year-old man with an 8-year history of heavily treated 
follicular lymphoma who was receiving a second treatment 
with 90Y-ibritumomab tiuxetan. On day 1 of the re-treatment 
the ibritumomab tiuxetan regimen, the patient received 
rituximab followed by 111In-ibritumomab tiuxtan without 
any difﬁ  culty. His biodistribution scan was unremarkable. 
One week later, he returned for the therapeutic dose. Again, 
rituximab was administered without any reaction but after 
less than 1.0 ml of 90Y-ibritumomab tiuxetan, the patient 
complained of chest pain. He was observed to have shallow 
respirations, hypotension and incontinence. He responded 
to resuscitative measures. A HAMA was measured and was 
strongly positive.
The anaphylactic reaction of our patient represents an 
immunologic response from a clonal population of “mem-
ory” B-cells. Presumably, his primary immune response 
occurred with his ﬁ  rst exposure to the dosimetric dose of 
111In-ibritumomab tiuxetan. With his initial therapeutic dose 
1 week later, he had no reaction. There is generally a lag of 
5–7 days before antibody levels start to rise in the primary 
immune response (Goldsby et al 2000). In a secondary 
immune response, the lag time before antibody levels start to 
rise is much shorter (1–2 days) and the levels are much higher 
(100 to 1000-fold higher) (Goldsby et al 2000). Thus, when 
patients are re-treated with murine and chimeric antibodies, 
their secondary immune response will result in more rapid 
antibody formation. Our patient’s re-treatment dosimetric 
dose likely incited a secondary immune response with 
ampliﬁ  cation of a HAMA-producing population of memory Biologics: Targets & Therapy 2007:1(3) 223
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B-cells which prompted his robust immunologic response to 
his therapeutic dose 6 days later.
The median time that HAMA antibodies remained 
detectable in the serum of previously untreated patients 
using 131I-tositumomab was 5.5 months (range 1.1–25.1) 
(Kaminski et al 2005). Our patient was nearly 2 years out 
from his initial treatment with radioimmunotherapy, and 
he may or not have had detectable HAMA in his serum 
prior to his dosimetric dose, but he clearly had maintained 
his amnestic response. While this is an unusual reaction 
even in patients with HAMA, this case illustrates that even 
heavily pretreated patients may have a robust immune 
response, and it would be prudent to check HAMA levels 
in all patients prior to re-treatment with radioimmuno-
therapy.50
Radiation ﬁ  brosis
A 75-year-old man with relapsed follicular non-Hodgkin 
lymphoma conﬁ  ned to a solitary lung mass was treated 
with  90Y-ibritumomab tiuxetan. Imaging with PET/CT 
showed a complete response 3 months after RIT. Thirteen 
months after RIT, his PET/CT scan showed an FDG-avid 
inﬁ  ltrate in the area of the prior lung mass. Bronchoscopy 
failed to review evidence of recurrent lymphoma and all 
cultures were negative. The patient was followed over the 
next 2 years with serial PET-CT scans (Figure 2). His latest 
scan 2 years after treatment showed persistent scarring in 
the area of previous disease with a marked decrease in SUV 
consistent with radiation ﬁ  brosis. Radiation-induced lung 
injury after therapy with 90Y-theraspheres was previously 
reported in the setting of intraarterial microspheres used to 
treat inoperable hepatic tumors. This occurs when there is 
a large shunt in the liver and the spheres become trapped in 
the small vessels of the lung. This is the ﬁ  rst case in which 
radiation-induced radiographic changes are reported after RIT 
for lymphoma. In this case the area of ﬁ  brosis was limited to 
the site of prior lymphoma. Radiation-induced lung injury
occurs after a latent period and is separated into 2 categories, 
which are acute and chronic phases (McDonald et al 1995; 
Lasky and Merrill 2005). Acute radiation pneumonitis occurs 
1–3 months after exposure. Chronic radiation-induced lung 
injury consists of ﬁ  brosis which may be seen 6 months after 
exposure and can progress over years.
This patient represents an unusual case in that there was 
a solitary lung mass which appeared similar to a solid tumor 
without evidence of disseminated disease. For this reason, 
we suspect that he may have received a concentrated dose of 
radiation, at a low-dose rate. The 111In-ibritumomab tiuxetan 
Panel 1 Panel 2
Panel 3 Panel 4
Figure 2 Panel 1 shows large left lung mass on CT scan with corresponding FDG-avidity, biopsy proven follicular lymphoma. Panel 2, 3 months later shows resolution of 
mass on CT scan and FDG-negative scan. Panel 3, 12 months after 90Y-ibritumomab tiuextan shows inﬁ  ltrative mass on CT scan and FDG-avid area apart from the heart. 
Bronchoscopy was negative for recurrent lymphoma and cultures were negative. Panel 4, 24 months after treatment there is residual scarring with decreased FDG-avidity.Biologics: Targets & Therapy 2007:1(3) 224
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with subsequent scanning with a gamma camera showed 
uptake in this mass and was used to estimate the radiation 
delivered to the region of interest (ROI) which we estimated 
to be a minimum of 980 rads. It is difﬁ  cult to compare the 
physiologic effect of a dose of external beam radiation at 
200 rads per fraction with that of continuous low-dose radia-
tion which is delivered by RIT.
Prior case reports have indicated that PET imaging may 
reveal FDG uptake in radiation pneumonitis (Lin et al 2000; 
Alavi et al 2002). PET positivity may be expected given the 
inﬂ  ammatory nature of the disorder, including inﬁ  ltration of 
leukocytes and pneumocyte proliferation (Alavi et al 2002). 
It was critically important in this case not to assume that the 
PET-positive inﬁ  ltrate was the result of recurrent lymphoma. 
Nearly 2 years elapsed before there was a signiﬁ  cant fall in 
the FDG-avidity in the left lung.
Serum sickness
A previously healthy 47-year-old woman was treated for 
follicular lymphoma, grade III, with CHOP-R followed by 
90Y-ibritumomab tiuxetan and rituximab. She developed a 
serum sickness-like illness 2 weeks after initiating 111In-
ibritumomab and while she was receiving post-RIT rituximab 
with fever, myalgias, arthralgias, and pleural and pericardial 
effusions. Despite anti-inﬂ  ammatory therapies her symptoms 
persisted for 10 months before ultimate resolution. Her symp-
toms responded to high dose steroids but with each attempt 
at tapering, inﬂ  ammatory markers increased and symptoms 
recurred. The addition of methrotrexate and colchicine 
was ineffective. With the combination of indomethicin and 
prednisone, doses were gradually tapered and discontin-
ued. In Figure 3 is shown a CT chest scan with pleural and 
pericardial effusions and the accompanying graph (Figure 4) 
is the time course of inﬂ  ammatory markers.
The occurrence of serum sickness after therapy with 
rituximab has been previously reported in 19 patients. In 
general, symptoms consisted of fever, myalgias, and arthral-
gias which responded promptly to corticosteroids. Serum 
sickness has been reported after rituximab in 2 patients 
with follicular lymphoma (Seror et al 2007), although other 
reported cases occurred in patients previously diagnosed 
with autoimmune disorders. This type of reaction has not 
been reported after RIT. In this patient, we are unable 
to determine which is the more likely causative agent 
rituximab or ibritumomab. Theoretically, the antibody 
90Y-ibritumomab may be more likely since it is a pure 
murine molecule, as opposed to rituximab, the majority of 
which is humanized. Serum testing was not deﬁ  nitive, as 
both HAMA and HACA were negative.
As monoclonal antibody use continues for various 
malignant and non-malignant diseases, and as 90Y-
ibritumomab tiuxetan is used earlier in the course of disease 
in patients with lymphoma when patients are less immu-
nocomprised, clinicians should be aware of this potential 
complication.
Summary
The development of anti-CD20 monoclonal antibody 
therapy has had a major impact on the treatment of B-cell 
NHL. It has been demonstrated in randomized clinical tri-
als in patients with diffuse large B-cell lymphoma that the 
addition of rituximab to CHOP has improved the overall 
response rate and improved survival. What role of radioim-
munotherapy will have on this subtype of lymphoma and 
in what setting remains to be deﬁ  ned. Current studies in 
previously untreated patients with stage I and II disease as 
well as in advanced disease may provide additional insight. 
Whether RIT will ﬁ  nd a place in the treatment algorithm of 
mantle cell lymphoma similarly awaits additional trials and 
maturation of data from the ECOG study and others. In a 
summary of SWOG trials in follicular lymphoma comparing 
studies from 1974 to 1983 and 1988 to 1994 and from 1998 
to 2000, it is apparent that the introduction of monoclonal 
antibody therapy has had a beneﬁ  cial effect on progres-
sion-free survival and overall survival, however, it is as 
yet not possible to deﬁ  ne differences between labeled and 
unlabeled antibody. Notwithstanding, it is clear that RIT 
can produce signiﬁ  cant responses in patients with relapsed 
follicular lymphoma including those patients refractory to 
rituximab. The place of RIT as a ﬁ  rst-line single agent or 
sequentially with chemotherapy needs to be determined 
by well-designed clinical trials. The results of the large 
Figure 3 CT scan with moderate pleural effusion and small pericardial effusion 
in patient with serum-sickness like syndrome. Both effusions rapidly cleared with 
steroid administration.Biologics: Targets & Therapy 2007:1(3) 225
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randomized Intergroup study may not be available for 
several years. It is also likely that by further elucidating the 
interaction of labeled and unlabeled monoclonal antibody 
and deﬁ  ning the mechanism of action of these agents on cell 
signaling a scientiﬁ  c rationale for designing optimal use of 
these agents will become a reality. We would envision that 
there will be patterns of expression of cell signaling proteins 
that will be predictive of response or resistance to antibody 
therapy and, may also, provide insight into combination of 
agents which will enhance response or overcome resistance. 
For lymphomas, apoptosis seems to be a critical pathway for 
cell death and it is likely that radioimmunotherapy will be 
demonstrated to have a role in apoptotic cell death through 
cell signaling mechanisms.
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